Alnylam Pharmaceuticals Inc experienced a significant decline of 11.9% this week.
Alnylam Pharmaceuticals Inc saw its stock price fall by 11.9% over the past week, closing at US$224.39. This decline continues a downward trend for the company, which has lost 44.04% year-to-date. The stock's performance reflects a challenging environment, with a 1-month decline of 15.85% and a current position within 9% of its 52-week range of US$197.81 to US$495.55.
Investor takeaway: Investors should monitor upcoming developments as the company's stock continues to show volatility.
Advertisement
Alnylam Pharmaceuticals Inc
ALNY.US
ALNY.US
Alnylam Pharmaceuticals Inc
WealthAwesomeMarket cap
$30.03B
P/E
37.8x
52W high
$495.55
52W low
$197.81
1W change
-2.88%
Beta
0.27
Analyst Price Targets
Based on 29 analysts covering ALNY · as of Oct 5, 2026
Wall Street analysts forecast ALNY stock price to rise 65.3% over the next 12 months.
Consensus
Buy4.31 / 5.00
Avg. Target
C$371.12
+65.3% Upside
Current Price
C$224.53
Last close
Analyst Breakdown (29 analysts)
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on ALNY's historical volatility
30-Day Vol
45.9%
Annualized
90-Day Vol
70.8%
Annualized
Trend (90d)
-50.0%
Annualized drift
90d Mean
C$187.81
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$211.56 | C$180.59 – C$247.82 |
| 60 trading days | C$199.33 | C$159.36 – C$249.32 |
| 90 trading days | C$187.81 | C$142.79 – C$247.03 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Alnylam Stock Down 11.9% This Week
The stock's latest volume was 1,941 shares, significantly lower than the 20-day average volume of 1,384,283 shares.
Bull case
Analysts have an average target price of US$371.12, indicating potential upside from current levels. This suggests that despite recent struggles, there may be room for recovery as market conditions change.
Bear case
The stock has not only declined significantly over the past week but also shows a downward trend compared to its 50-day and 200-day moving averages. This indicates ongoing bearish sentiment among investors, raising concerns about further declines in the near term.
Stock Performance Overview
Advertisement
This week, Alnylam Pharmaceuticals' stock experienced a decline of 11.9%, closing at US$224.39. The stock has been on a downward trajectory, with a 1-month loss of 15.85% and a year-to-date decline of 44.04%. The latest trading volume was 1,941 shares, which is significantly below the 20-day average of 1,384,283 shares, indicating reduced investor activity. The stock's beta is 0.27, suggesting lower volatility compared to the broader market.
Market Context and Technical Indicators
Alnylam's stock is currently trading below both its 50-day moving average of US$241.49 and its 200-day moving average of US$302.88, by 7.1% and 25.9% respectively. This positioning suggests persistent bearish sentiment among investors. The stock is currently within 9% of its 52-week range, reflecting a challenging environment. Despite the recent losses, the average analyst target price stands at US$371.12, indicating a potential upside of 65.4% from the current trading levels.
Future Considerations
Looking ahead, investors will be keen to observe any news or developments that may impact Alnylam's operations or market perception. The company's profit margin stands at 16.1%, and its return on equity is a strong 96.6%, suggesting robust underlying performance metrics that could influence future stock performance. With a P/E ratio of 37.08, the stock remains relatively high-valued compared to its earnings, prompting scrutiny as it continues to experience volatility.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
